Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Kaiyuan Gong, Baptiste Magnier, Salomé L'hostis, Fanny Borrely, Sébastien Le Bon, Nadine Houede, Adel Mamou, Laurent Maimoun, Pierre Olivier Kotzki, Vincent Boudousq
{"title":"Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning.","authors":"Kaiyuan Gong, Baptiste Magnier, Salomé L'hostis, Fanny Borrely, Sébastien Le Bon, Nadine Houede, Adel Mamou, Laurent Maimoun, Pierre Olivier Kotzki, Vincent Boudousq","doi":"10.3390/jpm14111068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objectives: </strong>Radioligandtherapy (RLT) with [177Lu]Lu-PSMA has been newly introduced as a routine treatment for metastatic castration-resistant prostate cancer (mCRPC). However, not all patients can tolerate the entire therapeutic sequence, and in some cases, the treatment may prove ineffective. In real-world conditions, the aim is to distinguish between patients who fully benefit from treatment (those who respond effectively and tolerate the entire therapeutic sequence) and those who do not respond or cannot tolerate the entire sequence. This study explores predictive factors to distinguish between fully beneficial RLT treatment patients (FBTP) and not fully beneficial RLT treatment patients (NFBTP). The objective was to enhance the understanding of predictive factors influencing RLT effectiveness and to highlight the significance of machine learning in optimizing patient selection for treatment planning.</p><p><strong>Methods: </strong>Data from 25 mCRPC patients, categorized as FBTP (11) or NFBTP (14) to RLT, were analyzed. The dataset included clinical, imaging, and biological parameters. Data analysis techniques, including exploratory data analysis and feature engineering, were used to develop machine learning models for predicting patient outcomes.</p><p><strong>Results: </strong>Imaging data analysis revealed statistically significant differences in the renal uptake intensity of Choline between the two groups. A discordance of FDG+ and PSMA- was identified as a potential indicator of NFBTP. The integration of biological data enhanced the model's predictive capability, achieving an accuracy of 0.92, a sensitivity of 0.96, and a precision of 0.96. Adding blood parameters like neutrophils, leukocytes, and alkaline phosphatase greatly increased prediction accuracy.</p><p><strong>Conclusions: </strong>This study emphasizes the significance of an integrated approach that merges imaging and biological data, thereby augmenting the predictive accuracy of patient outcomes in RLT with [177Lu]Lu-PSMA. In particular, including Choline PET among the imaging parameters provides unique insights into the predictive factors affecting RLT efficacy. This approach not only deepens the understanding of predictive factors but also underscores the utility of machine learning in refining the patient selection process for optimized treatment planning.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 11","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11595926/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14111068","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background/objectives: Radioligandtherapy (RLT) with [177Lu]Lu-PSMA has been newly introduced as a routine treatment for metastatic castration-resistant prostate cancer (mCRPC). However, not all patients can tolerate the entire therapeutic sequence, and in some cases, the treatment may prove ineffective. In real-world conditions, the aim is to distinguish between patients who fully benefit from treatment (those who respond effectively and tolerate the entire therapeutic sequence) and those who do not respond or cannot tolerate the entire sequence. This study explores predictive factors to distinguish between fully beneficial RLT treatment patients (FBTP) and not fully beneficial RLT treatment patients (NFBTP). The objective was to enhance the understanding of predictive factors influencing RLT effectiveness and to highlight the significance of machine learning in optimizing patient selection for treatment planning.

Methods: Data from 25 mCRPC patients, categorized as FBTP (11) or NFBTP (14) to RLT, were analyzed. The dataset included clinical, imaging, and biological parameters. Data analysis techniques, including exploratory data analysis and feature engineering, were used to develop machine learning models for predicting patient outcomes.

Results: Imaging data analysis revealed statistically significant differences in the renal uptake intensity of Choline between the two groups. A discordance of FDG+ and PSMA- was identified as a potential indicator of NFBTP. The integration of biological data enhanced the model's predictive capability, achieving an accuracy of 0.92, a sensitivity of 0.96, and a precision of 0.96. Adding blood parameters like neutrophils, leukocytes, and alkaline phosphatase greatly increased prediction accuracy.

Conclusions: This study emphasizes the significance of an integrated approach that merges imaging and biological data, thereby augmenting the predictive accuracy of patient outcomes in RLT with [177Lu]Lu-PSMA. In particular, including Choline PET among the imaging parameters provides unique insights into the predictive factors affecting RLT efficacy. This approach not only deepens the understanding of predictive factors but also underscores the utility of machine learning in refining the patient selection process for optimized treatment planning.

利用机器学习预测mCRPC对[177Lu]Lu-PSMA疗法的反应
背景/目的:采用[177Lu]Lu-PSMA的放射线治疗(RLT)已成为治疗转移性抗性前列腺癌(mCRPC)的一种新的常规疗法。然而,并非所有患者都能耐受整个治疗序列,在某些情况下,治疗可能被证明无效。在现实条件下,我们的目标是区分完全从治疗中获益的患者(有效应答并能耐受整个治疗序列的患者)和无应答或不能耐受整个治疗序列的患者。本研究探讨了区分完全受益于 RLT 治疗患者(FBTP)和非完全受益于 RLT 治疗患者(NFBTP)的预测因素。目的是加深对影响 RLT 疗效的预测因素的理解,并强调机器学习在优化治疗计划患者选择方面的意义:分析了25名mCRPC患者的数据,这些患者在接受RLT治疗时被分为FBTP(11名)或NFBTP(14名)。数据集包括临床、成像和生物学参数。数据分析技术包括探索性数据分析和特征工程,用于开发预测患者预后的机器学习模型:成像数据分析显示,两组患者肾脏对胆碱的摄取强度存在显著统计学差异。FDG+ 和 PSMA- 的不一致性被确定为 NFBTP 的潜在指标。生物数据的整合增强了模型的预测能力,准确度达到 0.92,灵敏度达到 0.96,精确度达到 0.96。加入中性粒细胞、白细胞和碱性磷酸酶等血液参数大大提高了预测准确性:本研究强调了综合方法的重要性,该方法融合了成像和生物数据,从而提高了使用[177Lu]Lu-PSMA进行RLT患者预后预测的准确性。尤其是将胆碱 PET 纳入成像参数,为影响 RLT 疗效的预测因素提供了独特的见解。这种方法不仅加深了对预测因素的理解,还强调了机器学习在完善患者选择过程以优化治疗计划方面的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信